GSK
Latest Trade
45.10USDChange
0.22(+0.49%)Volume
5,467,463Today's Range
-
45.4752 Week Range
-
46.85As of on the New York Stock Exchange ∙ Minimum 15 minute delay
Previous Close | 44.88 |
|---|---|
Open | 45.08 |
Volume | 5,467,463 |
3M AVG Volume | 87.20 |
Today's High | 45.47 |
Today's Low | 44.84 |
52 Week High | 46.85 |
52 Week Low | 33.53 |
Shares Out (MIL) | 5,031.74 |
Market Cap (MIL) | 112,046.20 |
Forward P/E | 14.76 |
Dividend (Yield %) | 4.90 |
India CCI OKs Acquisition Of Glaxosmithkline Asia Private
Glaxosmithkline Appoints Tony Wood As CSO Designate
23andMe Announces Extension Of GSK Collaboration And Update On Joint Immuno-Oncology Program
GlaxoSmithKline PLC is a global healthcare company. The Company researches and develops a range of products in three primary areas: Pharmaceuticals, Vaccines and Consumer Healthcare. Its product formulations include tablets, creams/ointments, inhalers, injections, liquids and sterile products. Its Pharmaceuticals business has a portfolio of established medicines in respiratory, human immunodeficiency virus (HIV), immuno-inflammation and oncology. Its Vaccines business has a portfolio of vaccines to help protect people from a range of diseases throughout their lives. Its vaccines tackle diseases, including pneumococcal disease, meningitis, hepatitis, rotavirus, whooping cough and influenza. Its Consumer Healthcare business combines science and consumer insights to create everyday healthcare brands that consumers trust, and experts recommend for oral health, pain relief, cold, flu and allergy, digestive health and vitamins, minerals and supplements.
Industry
Major Drugs
Contact Info
G S K House, 980 Great West Road
TW8 9GS
United Kingdom
+44.20.80475000
https://www.gsk.com/Executive Leadership
Jonathan Richard Symonds
Independent Non-Executive Chairman of the Board
Emma N. Walmsley
Chief Executive Officer, Executive Director
Iain James Mackay
Chief Financial Officer, Executive Director
Roger G. Connor
President - Global Vaccines
Brian McNamara
Chief Executive Officer - GSK Consumer Healthcare
Price To Earnings (TTM) | 19.34 |
|---|---|
Price To Sales (TTM) | 2.47 |
Price To Book (MRQ) | 5.38 |
Price To Cash Flow (TTM) | 11.70 |
Total Debt To Equity (MRQ) | 165.99 |
LT Debt To Equity (MRQ) | 134.42 |
Return on Investment (TTM) | 9.78 |
Return on Equity (TTM) | 6.27 |
GlaxoSmithKline and U.S. partner Vir Biotechnology will boost production of their antibody-based COVID-19 treatment by adding a second manufacturing plant to help meet soaring demand in the United States.
(The author is a Reuters Breakingviews columnist. The opinions expressed are their own.)
London's FTSE 100 slipped on Thursday on weakness in oil stocks and GlaxoSmithKline, while food delivery platform Deliveroo jumped on order growth hitting the top of its outlook range.
Unilever's strategy was under the investor microscope on Thursday after the consumer goods group effectively abandoned its 50 billion pound ($68 billion) pursuit of GlaxoSmithKline's consumer healthcare business.
Unilever PLC on Wednesday effectively abandoned its plans to buy GlaxoSmithKline's consumer healthcare business, saying that it would not raise its 50 billion pound ($68 billion) offer that GSK previously rejected.
London's FTSE 100 rose on Thursday led by mining stocks and Unilever after the consumer products maker dropped its plan to acquire GSK's healthcare business, while food delivery platform Deliveroo jumped on order growth hitting the top of its outlook range.
Shares in consumer goods giant Unilever inched roughly 2% higher on Thursday after it said late on Wednesday it would not raise its rejected 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare business.
GlaxoSmithKline said on Wednesday that Hal Barron will end his position as chief scientific officer in August after less than five years to run a new privately owned start-up biotech company.
Unilever signalled on Monday it would pursue a deal for GSK's consumer business, calling it a "strong strategic fit", but Unilever shares slid more than 8%, highlighting investors' doubts about its 50-billion-pound ($68.4 billion) offer.
Unilever faces a dilemma after its 50 billion pound ($68 billion) offer for GlaxoSmithKline's consumer healthcare assets was rejected -- should it raise the bid and risk overpaying or seek another route to expand in healthcare?
Alan Jope can no longer be accused of sitting on his hands. The Unilever boss on Monday signalled he would persevere with the attempted acquisition of GlaxoSmithKline’s consumer healthcare unit. But his rejected 50 billion pound offer was already pricey. Jope risks upsetting...
London's FTSE 100 rose on Monday as healthcare firm GlaxoSmithKline led gains after rejecting a 50-billion-pound takeover offer for its consumer products arm from Unilever, while energy and mining stocks also provided support.
* GSK AND PFIZER HOLD OUT FOR £60BN BID FOR CONSUMER HEALTH UNIT - FT
Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc's consumer products division, Bloomberg reported https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit...
Unilever Plc has held talks with banks about additional financing for a potential sweetened offer for GlaxoSmithKline Plc's consumer products division, Bloomberg reported https://www.bloomberg.com/news/articles/2022-01-16/unilever-is-said-to-weigh-raising-offer-for-glaxo-consumer-unit...
* UNILEVER HAS HELD TALKS WITH BANKS ABOUT ADDITIONAL FINANCING FOR POTENTIAL SWEETENED OFFER FOR GSK'S CONSUMER PRODUCTS DIVISION - BLOOMBERG NEWS Source text for Eikon: Further company coverage:
GlaxoSmithKline on Saturday said it had rejected a 50-billion-pound offer from Unilever for its consumer goods arm, saying it "fundamentally undervalued" the business and its future prospects and that it would stick to its plan of spinning off the unit.
* ARCELLX INC FILES FOR IPO OF UP TO $100 MILLION – SEC FILING
AstraZeneca, Eli Lilly, Regeneron and GlaxoSmithKline are among the biggest pharmaceutical companies to have developed COVID-19 treatments using a class of drugs called monoclonal antibodies, but the spread of the highly contagious Omicron variant has put the therapies'...
A World Health Organization (WHO) panel recommended use of two drugs by Eli Lilly, and GlaxoSmithKline and Vir Biotechnology for COVID-19 patients, adding treatment options as the fast-spreading Omicron variant renders many ineffective.
Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.